Buru Energy Limited (BRU.AX)
AUD 0.03
(-5.71%)
AUD 0.03
(-5.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.79 Million | -4.5 Million | -5.87 Million | -1.87 Million | -11.72 Million | -1.86 Million |
| Net Income | -5.11 Million | -32.77 Million | -10.75 Million | -28.82 Million | -27.53 Million | 29.73 Million |
| Depreciation & Amortization | 810 Thousand | 3.48 Million | 4.33 Million | 7.03 Million | 6.88 Million | 5.68 Million |
| Deferred income taxes | -69 Thousand | - | -10.23 Million | - | -14.59 Million | -376.99 Thousand |
| Stock-based compensation | 69 Thousand | - | 565 Thousand | - | 638 Thousand | 481 Thousand |
| Change in working capital | 2.07 Million | -464 Thousand | -372 Thousand | -217 Thousand | -284 Thousand | -104 Thousand |
| Other non-cash items | -5.56 Million | 25.25 Million | 10.57 Million | 20.13 Million | 23.16 Million | -37.29 Million |
| Investing Cash Flow | 1.08 Million | -9 Million | -5.74 Million | -5.69 Million | -15.4 Million | 51.91 Million |
| Investments in PPE | -3.91 Million | -9.01 Million | -5.76 Million | -5.69 Million | -15.4 Million | -12.81 Million |
| Acquisitions | 3000.00 | 12 Thousand | 15 Thousand | - | - | 64.04 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 5 Million | 225 Thousand | 92 Thousand | 323 Thousand | 1.53 Million | 677 Thousand |
| Financing Cash Flow | 7.26 Million | 7.75 Million | 13.79 Million | -3.41 Million | -4.31 Million | -2.86 Million |
| Debt repayment | -1.22 Million | -1.32 Million | -1.24 Million | -2.08 Million | -3.22 Million | -2.87 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -173 Thousand | - | - | - | - | - |
| Common Stock Issuance | 8.48 Million | 9.07 Million | 15.03 Million | - | - | 15 Thousand |
| Other Financing Activities | -1.05 Million | -1.32 Million | -1.24 Million | -1.32 Million | -1.09 Million | 15 Thousand |
| Accounts receivables | -3.02 Million | -613 Thousand | 1 Million | -686 Thousand | 1.45 Million | -1.12 Million |
| Accounts payables | 90 Thousand | -2.01 Million | -716 Thousand | -679 Thousand | 491 Thousand | -1.18 Million |
| Inventory | 1.06 Million | 712 Thousand | -1.28 Million | 960 Thousand | -2.14 Million | 1.02 Million |
| Other working capital | 3.94 Million | 1.45 Million | 624 Thousand | 188 Thousand | -93 Thousand | 1.18 Million |
| Cash at beginning of period | 17.92 Million | 23.72 Million | 21.42 Million | 32.41 Million | 64.01 Million | 16.85 Million |
| Cash at end of period | 18.19 Million | 17.92 Million | 23.72 Million | 21.42 Million | 32.41 Million | 64.01 Million |
| Capital Expenditure | -3.91 Million | -9.01 Million | -5.76 Million | -5.69 Million | -15.4 Million | -12.81 Million |
| Effect of forex changes on cash | -280 Thousand | -41 Thousand | 127 Thousand | -9000.00 | -149 Thousand | -30 Thousand |
| Net cash flow / Change in cash | 275 Thousand | -5.8 Million | 2.29 Million | -10.98 Million | -31.59 Million | 47.15 Million |
| Free Cash Flow | -11.71 Million | -13.52 Million | -11.64 Million | -7.56 Million | -27.13 Million | -14.67 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.68 Million | -5.11 Million | 879 Thousand | -5.99 Million | -32.77 Million | -23.32 Million |
| Depreciation & Amortization | 915 Thousand | 810 Thousand | 312 Thousand | 1.84 Million | 3.48 Million | 18.17 Million |
| Deferred income taxes | - | -69 Thousand | - | - | - | - |
| Stock-based compensation | - | 69 Thousand | - | 69 Thousand | - | - |
| Change in working capital | - | 2.07 Million | 1.98 Million | - | -464 Thousand | 1.38 Million |
| Other non-cash items | 371 Thousand | -5.56 Million | -2.08 Million | 1.56 Million | 25.25 Million | 24.05 Million |
| Investing Cash Flow | -1.95 Million | 1.08 Million | 1.55 Million | -470 Thousand | -9 Million | -1.12 Million |
| Investments in PPE | -5.32 Million | -3.91 Million | -3.8 Million | -107 Thousand | -9.01 Million | -1.12 Million |
| Acquisitions | - | 3000.00 | 3000.00 | - | 12 Thousand | - |
| Investment purchases | - | - | 363 Thousand | -363 Thousand | - | - |
| Sales/Maturities of investments | 3.36 Million | - | - | - | - | - |
| Other Investing Activities | - | 5 Million | 5 Million | -71 Thousand | 225 Thousand | 193 Thousand |
| Financing Cash Flow | -228 Thousand | 7.26 Million | 7.5 Million | -236 Thousand | 7.75 Million | -723 Thousand |
| Debt repayment | - | -1.22 Million | - | -236 Thousand | -1.32 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -173 Thousand | - | - | - | -47 Thousand |
| Common Stock Issuance | -21 Thousand | 8.48 Million | 8.48 Million | - | 9.07 Million | -47 Thousand |
| Other Financing Activities | -207 Thousand | -1.05 Million | 7.5 Million | -236 Thousand | -1.32 Million | -662 Thousand |
| Accounts receivables | - | -3.02 Million | -3.02 Million | - | -613 Thousand | -613 Thousand |
| Accounts payables | - | 90 Thousand | - | - | -2.01 Million | - |
| Inventory | - | 1.06 Million | 1.06 Million | - | 712 Thousand | 712 Thousand |
| Other working capital | - | 3.94 Million | 3.94 Million | - | 1.45 Million | 1.28 Million |
| Cash at beginning of period | 18.19 Million | 17.92 Million | 10.93 Million | 17.92 Million | 23.72 Million | 19 Million |
| Cash at end of period | 10.89 Million | 18.19 Million | 18.19 Million | 10.93 Million | 17.92 Million | 17.92 Million |
| Capital Expenditure | -5.32 Million | -3.91 Million | -3.8 Million | -107 Thousand | -9.01 Million | -1.12 Million |
| Effect of forex changes on cash | - | -280 Thousand | -277 Thousand | -3000.00 | -41 Thousand | 36 Thousand |
| Net cash flow / Change in cash | -7.3 Million | 275 Thousand | 7.26 Million | -6.98 Million | -5.8 Million | -1.07 Million |
| Free Cash Flow | -10.54 Million | -11.71 Million | -5.32 Million | -6.38 Million | -13.52 Million | -392 Thousand |
LEG
UOS
CYTO
KOV
BLKB
VMT